, /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) is celebrating its eight-year anniversary of being established in (U.S.
). In 2016, MTPA was created as a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), with the goal of developing and advancing the company's pipeline in the U.S.
while focusing on improving research in the areas of amyotrophic lateral sclerosis (ALS), erythropoietic protoporphyria (EPP), Parkinson's disease, spinal cord injury and systemic sclerosis. "For almost a decade, MTPA has been dedicated to advancing science and research to support underserved patient populations with complex needs including neurodegenerative diseases, inflammatory, and metabolic conditions," said , President, MTPA. "We're proud to continue the 300-year legacy of our parent company, MTPC in , here in the U.
S., where more than 5,000 people each year are diagnosed with ALS. We are excited to pursue promising medical advances as we seek new therapies for people struggling with debilitating diseases.
" Over the past eight years, MTPA has achieved success with RADICAVA (edaravone) and RADICAVA ORS (edaravone), the intravenous (IV) and oral formulations of its treatment for ALS. To date, more than 14,600 people with ALS in the U.S.
have received treatment with RADICAVA and/or RADICAVA ORS since the therapies became available in and , respectively. The treatments have been prescribed by over 2,300 healthcare professionals (HCPs) and about 80% of RADICAVA a.
